References
[1] Hu C. Grants supporting research in China. Eur Heart J 2018;39:2342-4.
[2] Hu C. Emergency Protective Measures and Strategies of Covid-19: From Lifestyle to Traditional Chinese Medicine. Clin Complement Med Pharmacol 2023;3:100089.
[3] Wang X, Hu D, Dang S, et al. Efficacy and Safety of Shensong Yangxin Capsules for Frequent VPCs in Congestive Heart Failure Study Group. Effects of Traditional Chinese Medicine Shensong Yangxin Capsules on Heart Rhythm and Function in Congestive Heart Failure Patients with Frequent Ventricular Premature Complexes: A Randomized, Double-blind, Multicenter Clinical Trial. Chin Med J (Engl) 2017;130:1639-47.
[4] Hua W, Gao RL, Zhao BC, et al. The Efficacy and Safety of Wenxin Keli in Patients with Frequent Premature Ventricular Contractions: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial. Chin Med J (Engl) 2015;128:2557-64.
[5] Xu Y, Li X, Zhang H, et al. China Tongxinluo Study for myocardial protection in patients with Acute Myocardial Infarction (CTS-AMI): Rationale and design of a randomized, double-blind, placebo-controlled, multicenter clinical trial. Am Heart J 2020;227:47-55.
[6] Li X, Zhang J, Huang J, et al. Efficacy and Safety of Qili Qiangxin Capsules for Chronic Heart Failure Study Group. A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of qili qiangxin capsules in patients with chronic heart failure. J Am Coll Cardiol 2013;62:1065-72.
[7] Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-12.
[8] The SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015;373:2103-16.
[9] Lonn EM, Bosch J, López-Jaramillo P, et al. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 2016;374:2009-20.
[10] Parati G, Kjeldsen S, Coca A, Cushman WC, Wang J. Adherence to Single-Pill Versus Free-Equivalent Combination Therapy in Hypertension: A Systematic Review and Meta-Analysis. Hypertension 2021;77:692-705.
[11] Smits WK, Lyras D, Lacy DB, Wilcox MH, Kuijper EJ. Clostridium difficile infection. Nat Rev Dis Primers 2016;2:16020.
[12] Rezzoagli C, Archetti M, Mignot I, Baumgartner M, Kümmerli R. Combining antibiotics with antivirulence compounds can have synergistic effects and reverse selection for antibiotic resistance in Pseudomonas aeruginosa. PLoS Biol 2020;18:e3000805.
[13] De Oliveira DMP, Bohlmann L, Conroy T, et al. Repurposing a neurodegenerative disease drug to treat Gram-negative antibiotic-resistant bacterial sepsis. Sci Transl Med 2020;12:eabb3791.
[14] Rodriguez B, Carusi A, Abi-Gerges N, et al. Human-based approaches to pharmacology and cardiology: an interdisciplinary and intersectorial workshop. Europace 2016;18:1287-98.
[15] Thille AW, Muller G, Gacouin A, et al. Effect of Postextubation High-Flow Nasal Oxygen With Noninvasive Ventilation vs High-Flow Nasal Oxygen Alone on Reintubation Among Patients at High Risk of Extubation Failure: A Randomized Clinical Trial. JAMA 2019;322:1465-75.
[16] Yancy WS Jr, Crowley MJ, Dar MS, et al. Comparison of Group Medical Visits Combined With Intensive Weight Management vs Group Medical Visits Alone for Glycemia in Patients With Type 2 Diabetes: A Noninferiority Randomized Clinical Trial. JAMA Intern Med 2020;180:70-9.
[17] Glenn AJ, Lo K, Jenkins DJA, et al. Relationship Between a Plant-Based Dietary Portfolio and Risk of Cardiovascular Disease: Findings From the Women’s  Health Initiative Prospective Cohort Study. J Am Heart Assoc 2021;10:e021515.
[18] Glenn AJ, Boucher BA, Kavcic CC, et al. Development of a Portfolio Diet Score and Its Concurrent and Predictive Validity Assessed by a Food Frequency Questionnaire. Nutrients 2021;13:2850.
[19] Writing Committee for the REMAP-CAP Investigators; Lawler PR, Derde LPG, van de Veerdonk FL, et al. Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial. JAMA 2023;329:1183-96.
[20] Volpp KG, Troxel AB, Mehta SJ, et al. Effect of Electronic Reminders, Financial Incentives, and Social Support on Outcomes After Myocardial Infarction: The HeartStrong Randomized Clinical Trial. JAMA Intern Med 2017;177:1093-101.
[21] Varghese GM, Dayanand D, Gunasekaran K, et al. INTREST Trial Investigators. Intravenous Doxycycline, Azithromycin, or Both for Severe Scrub Typhus. N Engl J Med 2023;388:792-803.
[22] Choueiri TK, Powles T, Albiges L, et al. COSMIC-313 Investigators. Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma. N Engl J Med 2023;388:1767-78.
[23] Eichhorst B, Niemann CU, Kater AP, et al. GCLLSG, the HOVON and Nordic CLL Study Groups, the SAKK, the Israeli CLL Association, and Cancer Trials Ireland. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia. N Engl J Med 2023;388:1739-54.
[24] Encarnación-Rosado J, Sohn ASW, Biancur DE, et al. Targeting pancreatic cancer metabolic dependencies through glutamine antagonism. Nat Cancer 2023; doi: 10.1038/s43018-023-00647-3.
[25] Tian J, Chen JH, Chao SX, et al. Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial. Nat Med 2023;29:458-66.
[26] Springfeld C, Ferrone CR, Katz MHG, et al. Neoadjuvant therapy for pancreatic cancer. Nat Rev Clin Oncol 2023;20:318-37.
[27] Eisinger S, Sarhan D, Boura VF, et al. Targeting a scavenger receptor on tumor-associated macrophages activates tumor cell killing by natural killer cells. Proc Natl Acad Sci U S A 2020;117:32005-16.
[28] Berindan-Neagoe I, Braicu C, Irimie A. Combining the chemotherapeutic effects of epigallocatechin 3-gallate with siRNA-mediated p53 knock-down results in synergic pro-apoptotic effects. Int J Nanomedicine 2012;7:6035-47.
[29] Yip HYK, Papa A. Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments. Cells 2021;10:659.
[30] Shi X, Shu L, Wang M, et al. Triple-Combination Immunogenic Nanovesicles Reshape the Tumor Microenvironment to Potentiate Chemo-Immunotherapy in Preclinical Cancer Models. Adv Sci (Weinh) 2023:e2204890.
[31] Adams S, Diamond JR, Hamilton E, et al. Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial. JAMA Oncol 2019;5:334-42.
[32] Delgado-Waldo I, Contreras-Romero C, Salazar-Aguilar S, et al. A triple-drug combination induces apoptosis in cervical cancer-derived cell lines. Front Oncol 2023;13:1106667.
[33] Menden MP, Wang D, Mason MJ, et al. Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen. Nat Commun 2019;10:2674.
[34] Eduati F, Utharala R, Madhavan D, et al. A microfluidics platform for combinatorial drug screening on cancer biopsies. Nat Commun 2018;9:2434.
[35] Gao P, Chang X, Zhang D, et al. Synergistic integration of metal nanoclusters and biomolecules as hybrid systems for therapeutic applications. Acta Pharm Sin B 2021;11:1175-99.
[36] Fu Y, Si A, Wei X, et al. Combining a machine-learning derived 4-lncRNA signature with AFP and TNM stages in predicting early recurrence of hepatocellular carcinoma. BMC Genomics 2023;24:89.
[37] Eduati F, Jaaks P, Wappler J, et al. Patient-specific logic models of signaling pathways from screenings on cancer biopsies to prioritize personalized combination therapies. Mol Syst Biol 2020;16:e8664.
[38] Nassar ZD, Mah CY, Centenera MM, et al. Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition. Mol Cancer Res 2020;18:1500-11.
[39] Demko ZP, Sharpless KB. Preparation of 5-substituted 1H-tetrazoles from nitriles in water. Demko ZP, Sharpless KB. J Org Chem 2001;66:7945-50.
[40] Tornøe CW, Christensen C, Meldal M. Peptidotriazoles on solid phase: [1,2,3]-triazoles by regiospecific copper(i)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides. J Org Chem 2002;67:3057-64.
[41] Agard NJ, Prescher JA, Bertozzi CR. A strain-promoted [3 + 2] azide-alkyne cycloaddition for covalent modification of biomolecules in living systems. J Am Chem Soc 2004;126:15046-7.
[42] WATSON JD, CRICK FH. Molecular structure of nucleic acids; a structure for deoxyribose nucleic acid. Nature 1953;171:737-8.
[43] WILKINS MH, STOKES AR, WILSON HR. Molecular structure of deoxypentose nucleic acids. Nature 1953;171:738-40.
[44] FRANKLIN RE, GOSLING RG. Molecular configuration in sodium thymonucleate. Nature 1953;171:740-1.
[45] Mi JQ, Chen SJ, Zhou GB, Yan XJ, Chen Z. Synergistic targeted therapy for acute promyelocytic leukaemia: a model of translational research in human cancer. J Intern Med 2015;278:627-42.
[46] Mao J, Wang Y, Zhang W, et al. Long-term correction of hemorrhagic diathesis in hemophilia A mice by an AAV-delivered hybrid FVIII composed of the human heavy chain and the rat light chain. Front Med 2022;16:584-95.
[47] Berg P, Sorensen MV, Rousing AQ, et al. Challenged Urine Bicarbonate Excretion as a Measure of Cystic Fibrosis Transmembrane Conductance Regulator Function in Cystic Fibrosis. Ann Intern Med 2022;175:1543-51.